JUPITER, Fla., March 14, 2012 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the industrial enzyme, bioenergy, and biopharmaceutical industries, announced today that it will launch FibreZyme® G5000, a next generation, high performance powder enzyme designed to improve paper quality and improve the economics of various pulp and paper manufacturing processes, in Booth #1065 at the Tissue World Americas conference and exhibition being held at the Miami Beach Convention Center in Miami, Florida from March 20th to March 23rd, 2012.
Thomas O'Shaughnessy, Vice President Sales & Marketing stated, "FibreZyme® G5000 is a great addition to our current FibreZyme® series of products and provides further evidence of the value-adding capabilities of Dyadic's C1 platform technology. FibreZyme® G5000 operates under wide pH and temperature ranges allowing for seamless integration into most pulp and paper manufacturing processes."
Specific attributes of FibreZyme® G5000 include the following:
FibreZyme® G5000 is produced using a variant of Dyadic's patented and proprietary C1 platform technology which Dyadic designated as the "white strain" process. Developed through sustained efforts at Dyadic's research and development facility in the Netherlands, the white strain produces significantly less background proteins, providing a clean background host for targeted production. These changes allow for more efficient and economical industrial scale production of highly targeted enzymes and proteins at greater purity levels. For more information about FibreZyme® G5000, please visit Dyadic's pulp and paper website at www.FibreZyme.com.
Tissue World Americas is the only conference and exhibition targeted at North and South American producers, converters, distributors, traders and suppliers of soft hygiene tissue paper. The event will include a technical conference covering new developments in the tissue business and provide a unique opportunity to learn about new techniques and methods to improve operations and profits.
Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzyme and protein products for the industrial enzyme, bioenergy, and biopharmaceutical industries. Please visit Dyadic's website at www.dyadic.com.
Cautionary Statement for Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.
|SOURCE Dyadic International, Inc.|
Copyright©2010 PR Newswire.
All rights reserved